Royal Bank Of Canada Curis Inc Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $0.99 $180 - $313	317 Added 13.21%	2,717 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.47 - $17.22 $132 - $4,838	-281 Reduced 10.48%	2,400 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $15.01 $316 - $6,424	-428 Reduced 13.77%	2,681 $2,000
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $3,274 - $11,207	-4,612 Reduced 59.73%	3,109 $2,000
Q1 2022 May 16, 2022	SELL	$2.31 - $5.13 $31,644 - $70,275	-13,699 Reduced 63.95%	7,721 $19,000
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $50,267 - $91,384	11,296 Added 111.58%	21,420 $101,000
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $12,262 - $15,637	1,767 Added 21.14%	10,124 $80,000
Q2 2021 Aug 16, 2021	BUY	$7.45 - $16.27 $62,259 - $135,968	8,357 New	8,357 $67,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.